Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults

Combined phase 2 outcomes through PAL-003 extension study

Nicola Longo, Roberto Zori, Melissa P. Wasserstein, Jerry Vockley, Barbara K. Burton, Celeste Decker, Mingjin Li, Kelly Lau, Joy Jiang, Kevin Larimore, Janet A. Thomas

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Deficiency of phenylalanine hydroxylase causes phenylketonuria (PKU) with elevated phenylalanine (Phe) levels and associated neuropsychiatric and neurocognitive symptoms. Pegvaliase (PEGylated phenylalanine ammonia lyase) is an investigational agent to lower plasma Phe in adults with PKU. This study aimed to characterize the long-term efficacy, safety, and immunogenicity of pegvaliase in adults with PKU. Methods: PAL-003 is an ongoing, open-label, long-term extension study of the pegvaliase dose-finding parent phase 2 studies. Participants continued the dose of pegvaliase from one of three parent studies, with dose adjustments to achieve a plasma Phe concentration between 60 and 600 μmol/L. Results: Mean (standard deviation [SD]) plasma Phe at treatment-naïve baseline for 80 participants in the parent studies was 1302.4 (351.5) μmol/L. In the 68 participants who entered the extension study, plasma Phe decreased 58.9 (39)% from baseline, to 541.6 (515.5) μmol/L at Week 48 of treatment. Plasma Phe concentrations ≤120 μmol/L, ≤360 μmol/L, and ≤ 600 μmol/L were achieved by 78.7, 80.0, and 82.5% of participants, respectively. Mean (SD) protein intake at baseline was 69.4 (40.4) g/day (similar to the recommended intake for the unaffected population) and remained stable throughout the study. All participants experienced adverse events (AEs), which were limited to mild or moderate severity in most (88.8%); the most common AEs were injection-site reaction (72.5%), injection-site erythema (67.5%), headache (67.5%), and arthralgia (65.0%). The AE rate decreased from 58.3 events per person-year in the parent studies to 18.6 events per person-year in the extension study. Conclusions: Pegvaliase treatment in adults with PKU produced meaningful and persistent reductions in mean plasma Phe concentration with a manageable safety profile for most subjects that continued with long-term treatment. Trial registration: ClinicalTrials.gov, NCT00924703. Registered June 18, 2009, https://clinicaltrials.gov/ct2/show/NCT00924703

Original languageEnglish (US)
Article number108
JournalOrphanet Journal of Rare Diseases
Volume13
Issue number1
DOIs
StatePublished - Jul 4 2018

Fingerprint

Phenylketonurias
Phenylalanine
Safety
Phenylalanine Ammonia-Lyase
Social Adjustment
Injections
Arthralgia
Population Dynamics
Therapeutics
Erythema
Headache

Keywords

  • Pegvaliase
  • Phenylketonuria
  • PKU
  • Recombinant Anabaena variabilis PEGylated phenylalanine ammonia lyase

ASJC Scopus subject areas

  • Genetics(clinical)
  • Pharmacology (medical)

Cite this

Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults : Combined phase 2 outcomes through PAL-003 extension study. / Longo, Nicola; Zori, Roberto; Wasserstein, Melissa P.; Vockley, Jerry; Burton, Barbara K.; Decker, Celeste; Li, Mingjin; Lau, Kelly; Jiang, Joy; Larimore, Kevin; Thomas, Janet A.

In: Orphanet Journal of Rare Diseases, Vol. 13, No. 1, 108, 04.07.2018.

Research output: Contribution to journalArticle

Longo, Nicola ; Zori, Roberto ; Wasserstein, Melissa P. ; Vockley, Jerry ; Burton, Barbara K. ; Decker, Celeste ; Li, Mingjin ; Lau, Kelly ; Jiang, Joy ; Larimore, Kevin ; Thomas, Janet A. / Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults : Combined phase 2 outcomes through PAL-003 extension study. In: Orphanet Journal of Rare Diseases. 2018 ; Vol. 13, No. 1.
@article{c1bfcc5888574baf95d4aae3d1166dda,
title = "Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults: Combined phase 2 outcomes through PAL-003 extension study",
abstract = "Background: Deficiency of phenylalanine hydroxylase causes phenylketonuria (PKU) with elevated phenylalanine (Phe) levels and associated neuropsychiatric and neurocognitive symptoms. Pegvaliase (PEGylated phenylalanine ammonia lyase) is an investigational agent to lower plasma Phe in adults with PKU. This study aimed to characterize the long-term efficacy, safety, and immunogenicity of pegvaliase in adults with PKU. Methods: PAL-003 is an ongoing, open-label, long-term extension study of the pegvaliase dose-finding parent phase 2 studies. Participants continued the dose of pegvaliase from one of three parent studies, with dose adjustments to achieve a plasma Phe concentration between 60 and 600 μmol/L. Results: Mean (standard deviation [SD]) plasma Phe at treatment-na{\"i}ve baseline for 80 participants in the parent studies was 1302.4 (351.5) μmol/L. In the 68 participants who entered the extension study, plasma Phe decreased 58.9 (39){\%} from baseline, to 541.6 (515.5) μmol/L at Week 48 of treatment. Plasma Phe concentrations ≤120 μmol/L, ≤360 μmol/L, and ≤ 600 μmol/L were achieved by 78.7, 80.0, and 82.5{\%} of participants, respectively. Mean (SD) protein intake at baseline was 69.4 (40.4) g/day (similar to the recommended intake for the unaffected population) and remained stable throughout the study. All participants experienced adverse events (AEs), which were limited to mild or moderate severity in most (88.8{\%}); the most common AEs were injection-site reaction (72.5{\%}), injection-site erythema (67.5{\%}), headache (67.5{\%}), and arthralgia (65.0{\%}). The AE rate decreased from 58.3 events per person-year in the parent studies to 18.6 events per person-year in the extension study. Conclusions: Pegvaliase treatment in adults with PKU produced meaningful and persistent reductions in mean plasma Phe concentration with a manageable safety profile for most subjects that continued with long-term treatment. Trial registration: ClinicalTrials.gov, NCT00924703. Registered June 18, 2009, https://clinicaltrials.gov/ct2/show/NCT00924703",
keywords = "Pegvaliase, Phenylketonuria, PKU, Recombinant Anabaena variabilis PEGylated phenylalanine ammonia lyase",
author = "Nicola Longo and Roberto Zori and Wasserstein, {Melissa P.} and Jerry Vockley and Burton, {Barbara K.} and Celeste Decker and Mingjin Li and Kelly Lau and Joy Jiang and Kevin Larimore and Thomas, {Janet A.}",
year = "2018",
month = "7",
day = "4",
doi = "10.1186/s13023-018-0858-7",
language = "English (US)",
volume = "13",
journal = "Orphanet Journal of Rare Diseases",
issn = "1750-1172",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults

T2 - Combined phase 2 outcomes through PAL-003 extension study

AU - Longo, Nicola

AU - Zori, Roberto

AU - Wasserstein, Melissa P.

AU - Vockley, Jerry

AU - Burton, Barbara K.

AU - Decker, Celeste

AU - Li, Mingjin

AU - Lau, Kelly

AU - Jiang, Joy

AU - Larimore, Kevin

AU - Thomas, Janet A.

PY - 2018/7/4

Y1 - 2018/7/4

N2 - Background: Deficiency of phenylalanine hydroxylase causes phenylketonuria (PKU) with elevated phenylalanine (Phe) levels and associated neuropsychiatric and neurocognitive symptoms. Pegvaliase (PEGylated phenylalanine ammonia lyase) is an investigational agent to lower plasma Phe in adults with PKU. This study aimed to characterize the long-term efficacy, safety, and immunogenicity of pegvaliase in adults with PKU. Methods: PAL-003 is an ongoing, open-label, long-term extension study of the pegvaliase dose-finding parent phase 2 studies. Participants continued the dose of pegvaliase from one of three parent studies, with dose adjustments to achieve a plasma Phe concentration between 60 and 600 μmol/L. Results: Mean (standard deviation [SD]) plasma Phe at treatment-naïve baseline for 80 participants in the parent studies was 1302.4 (351.5) μmol/L. In the 68 participants who entered the extension study, plasma Phe decreased 58.9 (39)% from baseline, to 541.6 (515.5) μmol/L at Week 48 of treatment. Plasma Phe concentrations ≤120 μmol/L, ≤360 μmol/L, and ≤ 600 μmol/L were achieved by 78.7, 80.0, and 82.5% of participants, respectively. Mean (SD) protein intake at baseline was 69.4 (40.4) g/day (similar to the recommended intake for the unaffected population) and remained stable throughout the study. All participants experienced adverse events (AEs), which were limited to mild or moderate severity in most (88.8%); the most common AEs were injection-site reaction (72.5%), injection-site erythema (67.5%), headache (67.5%), and arthralgia (65.0%). The AE rate decreased from 58.3 events per person-year in the parent studies to 18.6 events per person-year in the extension study. Conclusions: Pegvaliase treatment in adults with PKU produced meaningful and persistent reductions in mean plasma Phe concentration with a manageable safety profile for most subjects that continued with long-term treatment. Trial registration: ClinicalTrials.gov, NCT00924703. Registered June 18, 2009, https://clinicaltrials.gov/ct2/show/NCT00924703

AB - Background: Deficiency of phenylalanine hydroxylase causes phenylketonuria (PKU) with elevated phenylalanine (Phe) levels and associated neuropsychiatric and neurocognitive symptoms. Pegvaliase (PEGylated phenylalanine ammonia lyase) is an investigational agent to lower plasma Phe in adults with PKU. This study aimed to characterize the long-term efficacy, safety, and immunogenicity of pegvaliase in adults with PKU. Methods: PAL-003 is an ongoing, open-label, long-term extension study of the pegvaliase dose-finding parent phase 2 studies. Participants continued the dose of pegvaliase from one of three parent studies, with dose adjustments to achieve a plasma Phe concentration between 60 and 600 μmol/L. Results: Mean (standard deviation [SD]) plasma Phe at treatment-naïve baseline for 80 participants in the parent studies was 1302.4 (351.5) μmol/L. In the 68 participants who entered the extension study, plasma Phe decreased 58.9 (39)% from baseline, to 541.6 (515.5) μmol/L at Week 48 of treatment. Plasma Phe concentrations ≤120 μmol/L, ≤360 μmol/L, and ≤ 600 μmol/L were achieved by 78.7, 80.0, and 82.5% of participants, respectively. Mean (SD) protein intake at baseline was 69.4 (40.4) g/day (similar to the recommended intake for the unaffected population) and remained stable throughout the study. All participants experienced adverse events (AEs), which were limited to mild or moderate severity in most (88.8%); the most common AEs were injection-site reaction (72.5%), injection-site erythema (67.5%), headache (67.5%), and arthralgia (65.0%). The AE rate decreased from 58.3 events per person-year in the parent studies to 18.6 events per person-year in the extension study. Conclusions: Pegvaliase treatment in adults with PKU produced meaningful and persistent reductions in mean plasma Phe concentration with a manageable safety profile for most subjects that continued with long-term treatment. Trial registration: ClinicalTrials.gov, NCT00924703. Registered June 18, 2009, https://clinicaltrials.gov/ct2/show/NCT00924703

KW - Pegvaliase

KW - Phenylketonuria

KW - PKU

KW - Recombinant Anabaena variabilis PEGylated phenylalanine ammonia lyase

UR - http://www.scopus.com/inward/record.url?scp=85049532078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049532078&partnerID=8YFLogxK

U2 - 10.1186/s13023-018-0858-7

DO - 10.1186/s13023-018-0858-7

M3 - Article

VL - 13

JO - Orphanet Journal of Rare Diseases

JF - Orphanet Journal of Rare Diseases

SN - 1750-1172

IS - 1

M1 - 108

ER -